As of 2025-07-02, the Intrinsic Value of Nirvana Life Sciences Inc (NIRV.CN) is -0.36 CAD. This NIRV.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.11 CAD, the upside of Nirvana Life Sciences Inc is -438.67%.
Based on its market price of 0.11 CAD and our intrinsic valuation, Nirvana Life Sciences Inc (NIRV.CN) is overvalued by 438.67%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.36 - -0.36 | -0.36 | -438.67% |
| DDM - Stable | (0.89) - (3.47) | (2.18) | -2177.3% |
| DDM - Multi | (2.23) - (6.66) | (3.33) | -3274.0% |
| Market Cap (mil) | 0.51 |
| Beta | 0.59 |
| Outstanding shares (mil) | 4.82 |
| Enterprise Value (mil) | 0.60 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.71% |
| Cost of Debt | 5.00% |
| WACC | 7.49% |